Key statistics dashboard for Calidi Biotherapeutics, Inc. (CLDI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.
Stock Data
| Price | $1.17 |
| Market Cap | $1M |
| Beta | 1.42 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.02 |
| Price / Book | 0.53 |
| P/S | 0.00 |
| P/FCF | -0.03 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 1.68 |
| Quick Ratio | 1.68 |
| Cash Ratio | 1.26 |
| Debt / Equity | 0.62 |
| Debt / Assets | 26.96% |
| Interest Coverage | -114.43 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -29.02 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.21 |
| Cash per share | 2.88 |
| FCF per share | -12.58 |
| Tangible Book Value per share | 2.21 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: CANF · CMND · CNSP · KZIA · QLGN · SILO · SNGX
Explore sector: Healthcare · Biotechnology
More sections of CLDI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks